Androgen receptor structural and functional elements: Role and regulation in prostate cancer

被引:184
作者
Dehm, Scott M.
Tindall, Donald J.
机构
[1] Mayo Clin, Coll Med, Dept Urol, Rochester, MN 55905 USA
[2] Mayo Clin, Coll Med, Dept Biochem, Rochester, MN 55905 USA
[3] Mayo Clin, Coll Med, Dept Mol Biol, Rochester, MN 55905 USA
关键词
LIGAND-INDEPENDENT ACTIVATION; BINDING DOMAIN; TRANSACTIVATION DOMAIN; MOLECULAR-MECHANISMS; TERMINAL DOMAIN; CELL-GROWTH; GENE; INTERDOMAIN; RESISTANCE; EXPRESSION;
D O I
10.1210/me.2007-0223
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The androgen receptor (AR) is a nuclear receptor transcription factor that mediates the cellular actions of androgens, the male sex steroids. Androgen-dependent tissues, such as the prostate, rely on androgen action for their development as well as their maintenance in adulthood. This requirement is exploited during systemic therapy of prostate cancer, which is initially an androgen-dependent disease. Indeed, androgen ablation, which prevents the production or blocks the action of androgens, inhibits prostate cancer growth. Invariably, the disease recurs with a phenotype resistant to further hormonal manipulations. However, this so-called androgen depletion-independent prostate cancer remains dependent on a functional AR for growth. Many studies have focused on the mechanistic and structural basis of AR activation with the important goal of understanding how the AR is activated at this stage of the disease. In this review, we summarize how these studies have revealed important functional domains in the AR protein and have provided initial clues to their role in prostate cancer development and progression. A comprehensive understanding of the role and functional relationships between these AR domains could lead to the development of novel AR directed therapies for prostate cancer.
引用
收藏
页码:2855 / 2863
页数:9
相关论文
共 85 条
[51]   Activation of nuclear receptors: A perspective from structural genomics [J].
Li, Y ;
Lambert, MH ;
Xu, HE .
STRUCTURE, 2003, 11 (07) :741-746
[52]   Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer [J].
Liao, XB ;
Tang, SQ ;
Thrasher, JB ;
Griebling, TL ;
Li, BY .
MOLECULAR CANCER THERAPEUTICS, 2005, 4 (04) :505-515
[53]  
Lin BY, 1999, CANCER RES, V59, P4180
[54]   Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? [J].
Litvinov, IV ;
De Marzo, AM ;
Isaacs, JT .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (07) :2972-2982
[55]  
Ma H, 1999, MOL CELL BIOL, V19, P6164
[56]   Structural evidence for ligand specificity in the binding domain of the human androgen receptor -: Implications for pathogenic gene mutations [J].
Matias, PM ;
Donner, P ;
Coelho, R ;
Thomaz, M ;
Peixoto, C ;
Macedo, S ;
Otto, N ;
Joschko, S ;
Scholz, P ;
Wegg, A ;
Bäsler, S ;
Schäfer, M ;
Egner, U ;
Carrondo, MA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (34) :26164-26171
[57]   Structural basis for the glucocorticoid response in a mutant human androgen receptor (ARccr) derived from an androgen-independent prostate cancer [J].
Matias, PM ;
Carrondo, MA ;
Coelho, R ;
Thomaz, M ;
Zhao, XY ;
Wegg, A ;
Crusius, K ;
Egner, U ;
Donner, P .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (07) :1439-1446
[58]   Molecular mechanisms of androgen receptor-mediated gene regulation: structure-function analysis of the AF-1 domain [J].
McEwan, IJ .
ENDOCRINE-RELATED CANCER, 2004, 11 (02) :281-293
[59]   A novel inducible transactivation domain in the androgen receptor:: implications for PRK in prostate cancer [J].
Metzger, E ;
Müller, JM ;
Ferrari, S ;
Buettner, R ;
Schüle, R .
EMBO JOURNAL, 2003, 22 (02) :270-280
[60]   Steroid-induced androgen receptor-oestradiol receptor β-Src complex triggers prostate cancer cell proliferation [J].
Migliaccio, A ;
Castoria, G ;
Di Domenico, M ;
de Falco, A ;
Bilancio, A ;
Lombardi, M ;
Barone, MV ;
Ametrano, D ;
Zannini, MS ;
Abbondanza, C ;
Auricchio, F .
EMBO JOURNAL, 2000, 19 (20) :5406-5417